<DOC>
	<DOCNO>NCT00948259</DOCNO>
	<brief_summary>The purpose study evaluate 4 escalate dos 20 week NP031112 safe tolerate patient Alzheimer´s disease .</brief_summary>
	<brief_title>Safety Study Glycogen Synthase Kinase 3 ( GSK3 ) Inhibitor Patients With Alzheimer´s Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>1 . Men woman ( nonchildbearing potential ) diagnosis probable Alzheimer 's disease accord NINCDSADRDA clinical criterion . 2 . Age 60 85 year ( patient 85 year could include previous assessment investigator agreement sponsor ) 3 . MRI CTscan assessment within 12 month baseline corroborate clinical diagnosis ( diffuse brain atrophy predominate medial temporal region ) exclude potential cause dementia , especially cerebrovascular lesion ( see exclusion criterion , number 3 ) . 4 . Mild moderate stage Alzheimer 's disease accord MMSE 1626 . 5 . Modified Hachinski ischemic score equal 4 . 6 . Geriatric Depression Scale equal 7 . 7 . Female patient must either surgically sterilize least 1 year postmenopausal ( confirm FSH &gt; 20 , woman surgically sterilize ) . 8 . A caregiver/nurse available living household , interact patient assure correct preparation administration study drug patient . 9 . Patients live home old people 's home . 10 . General health status acceptable participation 6 month clinical trial . 11 . Ability swallow 100 150 ml water suspension . 12 . No dailyregular/chronic intake medication act central nervous system , immunosuppressant , steroid nonsteroid antiinflammatory agent except follow allow treatment : SSRIs antidepressant administer stable well tolerate dose two month prior baseline evaluation follow drug stable well tolerate dose symptomatic treatment mild behavioral disorder , sleep onsetinsomnia mild depressive mood : Risperidon max 1mg/day Quetiapin max 25mg/day Zolpidem max 10mg even Lorazepam max 1mg/day Triazolam max 0,25mg/day Alprazolam max 1mg/day Mirtazapin max 30mg/day Hydromorphon max 4mg/day Levodopa max 50mg t.i.d treatment ageassociated extrapyramidal syndrome restlesslegssyndrome Acetylsalicylic acid max 100mg/day antiplatelet agent . Nonsteroid antirheumatics concomitant medication take per request 13 . No history treatment Warfarin , Digitoxin Coumarin ( include derivative ) within 1 month prior baseline . Chronic treatment heparin s.c. anticoagulant digoxin treatment heart disease allow . 14 . Other drug metabolize CYP3A4 wide therapeutic window permit dose regimen stable well tolerate least 1 month prior baseline . 15 . Stable pharmacological treatment chronic condition least one month prior screen . 16 . Treatment stable well tolerate dose one approve AcetylcholinesteraseInhibitors ( Donepezil , Galantamine Rivastigmine ) least 2 month prior baseline evaluation . Dosage Acetylcholineesterase inhibitor increase ongoing study . 17 . No history treatment Memantine within 3 month prior baseline evaluation . Patients stable well tolerate dose Memantine allow include study . 18 . Signed informed consent patient prior initiation study specific procedure 1 . Failure perform screen baseline examination . 2 . Hospitalization change chronic concomitant medication within 1 month prior screening period . 3 . Clinical , laboratory neuroimaging finding consistent : primary degenerative dementia , ( dementia Lewy body , frontotemporal dementia , Huntington 's disease , JacobCreutzfeld Disease , Down 's syndrome , etc ) neurodegenerative condition ( Parkinson 's disease , amyotrophic lateral sclerosis , etc . ) cerebrovascular disease ( major infarct , one strategic multiple lacunar infarct , extensive white matter lesion ) central nervous system disease ( severe head trauma , tumor , subdural haematoma space occupy process , etc . ) seizure disorder infectious , metabolic systemic disease affect central nervous system ( syphilis , present hypothyroidism , present vitamin B12 folate deficiency , serum electrolyte normal range , juvenile onset diabetes mellitus , etc . ) 4 . A current DSMIV diagnosis active major depression , schizophrenia bipolar disorder . 5 . Clinically significant , advanced unstable disease may interfere evaluation may bias assessment clinical mental status patient put patient special risk , : chronic liver disease , liver function test ( LFT ) abnormalities sign hepatic insufficiency respiratory insufficiency renal insufficiency ( serum creatinine &gt; 2mg/dl creatinine clearance ≤ 60 mL/min accord CockgroftGault formula ) . heart disease ( myocardial infarction , unstable angina , heart failure , cardiomyopathy within 6 month screen ) bradycardia ( heart beat &lt; 50/min . ) tachycardia ( heart beat &gt; 95/min . ) hypertension hypotension well control unstable &gt; 2 month prior baseline . AV block ( type II / Mobitz II type III ) , congenital long QT syndrome , sinus node dysfunction prolong QTcBinterval ( male &gt; 450 female &gt; 470 msec ) uncontrolled diabetes malignant tumor within last 5 year except skin malignancy ( melanoma ) indolent prostate cancer metastases 6 . Disability may prevent subject complete study requirement ( e.g. , blindness , deafness , severe language difficulty , etc . ) 7 . Women fertile child bear potential . 8 . Anticoagulant treatment heparin i.v . 9 . Chronic drug intake : drug metabolize CYP3A4 narrow therapeutic window ( i.e . warfarin , digitoxin , … ) . antidepressant , benzodiazepine , neuroleptic sedative except define allow inclusion criterion number 12 protonpump inhibitor antiepileptics anticholinergic nootropics centrally active antihypertensive drug ( clonidine , alphamethyl dopa , guanidine , guanfacine , … ) opioid contain analgesic nonsteroid antiinflammatory agent ( except take concomitant medication per request define inclusion criterion number 12 ) , corticosteroids immunosuppressant memantine , lithium inhibitor GSK3 enzyme 10 . Suspected known drug alcohol abuse . 11 . Suspected known allergy component study treatment . 12 . Enrolment another investigational study intake investigational drug within previous 3 month . 13 . Any condition opinion investigator make patient unsuitable inclusion .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>safety</keyword>
	<keyword>GSK inhibitor</keyword>
	<keyword>Alzheimer</keyword>
</DOC>